Strategies for Optimizing the Response of Cancer and Normal Tissues to Radiation

Overview

Journal Nat Rev Drug Discov

Specialty Pharmacology

Date 2013 Jul 2

PMID 23812271

Citations 184

Authors

Everett J Moding

Michael B Kastan

David G Kirsch

Affiliations

Soon will be listed here.

Abstract

Approximately 50% of all patients with cancer receive radiation therapy at some point during the course of their treatment, and the majority of these patients are treated with curative intent. Despite recent advances in the planning of radiation treatment and the delivery of image-guided radiation therapy, acute toxicity and potential long-term side effects often limit the ability to deliver a sufficient dose of radiation to control tumours locally. In the past two decades, a better understanding of the hallmarks of cancer and the discovery of specific signalling pathways by which cells respond to radiation have provided new opportunities to design molecularly targeted therapies to increase the therapeutic window of radiation therapy. Here, we review efforts to develop approaches that could improve outcomes with radiation therapy by increasing the probability of tumour cure or by decreasing normal tissue toxicity.

Citing Articles

AnomalGRN: deciphering single-cell gene regulation network with graph anomaly detection.

Zhou Z, Wei J, Liu M, Zhuo L, Fu X, Zou Q BMC Biol. 2025; 23(1):73.

PMID: 40069807 PMC: 11900578. DOI: 10.1186/s12915-025-02177-z.

Inflammation in cancer: therapeutic opportunities from new insights.

Xie Y, Liu F, Wu Y, Zhu Y, Jiang Y, Wu Q Mol Cancer. 2025; 24(1):51.

PMID: 39994787 PMC: 11849313. DOI: 10.1186/s12943-025-02243-8.

Anatomical zone and tissue type impacts the repeatability of quantitative MRI parameters and radiomic features for longitudinal monitoring of treatment response in the prostate.

Wang Y, Tadimalla S, Holloway L, Thiruthaneeswaran N, Haworth A MAGMA. 2025; .

PMID: 39985650 DOI: 10.1007/s10334-025-01231-9.

Repurposing radiosensitising medicines for radiotherapy: an overview.

Low J, Rodriguez-Berriguete G, Higgins G BMJ Oncol. 2025; 3(1):e000192.

PMID: 39886153 PMC: 11235008. DOI: 10.1136/bmjonc-2023-000192.

Keratin/chitosan film promotes wound healing in rats with combined radiation-wound injury.

Wang Y, Xin T, Deng H, Chen J, Tang S, Liu L J Mater Sci Mater Med. 2025; 36(1):15.

PMID: 39869238 PMC: 11772442. DOI: 10.1007/s10856-025-06860-z.

References

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

Liu P, Cheng H, Roberts T, Zhao J . Targeting the phosphoinositide 3-kinase pathway in cancer. Nat Rev Drug Discov. 2009; 8(8):627-44. PMC: 3142564. DOI: 10.1038/nrd2926. View

Eriksson D, Stigbrand T . Radiation-induced cell death mechanisms. Tumour Biol. 2010; 31(4):363-72. DOI: 10.1007/s13277-010-0042-8. View

Fournel P, Robinet G, Thomas P, Souquet P, Lena H, Vergnenegre A . Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01.... J Clin Oncol. 2005; 23(25):5910-7. DOI: 10.1200/JCO.2005.03.070. View

Kang S, Rabbani Z, Folz R, Golson M, Huang H, Yu D . Overexpression of extracellular superoxide dismutase protects mice from radiation-induced lung injury. Int J Radiat Oncol Biol Phys. 2003; 57(4):1056-66. DOI: 10.1016/s0360-3016(03)01369-5. View

Maity A, Koumenis C . Location, location, location-makes all the difference for hypoxia in lung tumors. Clin Cancer Res. 2010; 16(19):4685-7. PMC: 3625627. DOI: 10.1158/1078-0432.CCR-10-2004. View

Schreiber R, Old L, Smyth M . Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science. 2011; 331(6024):1565-70. DOI: 10.1126/science.1203486. View

Ramanan S, Kooshki M, Zhao W, Hsu F, Riddle D, Robbins M . The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation. Int J Radiat Oncol Biol Phys. 2009; 75(3):870-7. PMC: 2789462. DOI: 10.1016/j.ijrobp.2009.06.059. View

Gudkov A, Komarova E . The role of p53 in determining sensitivity to radiotherapy. Nat Rev Cancer. 2003; 3(2):117-29. DOI: 10.1038/nrc992. View

10.

Purhonen S, Palm J, Rossi D, Kaskenpaa N, Rajantie I, Yla-Herttuala S . Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A. 2008; 105(18):6620-5. PMC: 2365563. DOI: 10.1073/pnas.0710516105. View

11.

de Palma M, Venneri M, Galli R, Sergi Sergi L, Politi L, Sampaolesi M . Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell. 2005; 8(3):211-26. DOI: 10.1016/j.ccr.2005.08.002. View

12.

Chen J, Li Y, Yu T, McKay R, Burns D, Kernie S . A restricted cell population propagates glioblastoma growth after chemotherapy. Nature. 2012; 488(7412):522-6. PMC: 3427400. DOI: 10.1038/nature11287. View

13.

Oltersdorf T, Elmore S, Shoemaker A, Armstrong R, Augeri D, Belli B . An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 2005; 435(7042):677-81. DOI: 10.1038/nature03579. View

14.

Choudhury A, Nelson L, Teo M, Chilka S, Bhattarai S, Johnston C . MRE11 expression is predictive of cause-specific survival following radical radiotherapy for muscle-invasive bladder cancer. Cancer Res. 2010; 70(18):7017-26. PMC: 2941719. DOI: 10.1158/0008-5472.CAN-10-1202. View

15.

Gupta A, McKenna W, Weber C, Feldman M, Goldsmith J, Mick R . Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res. 2002; 8(3):885-92. View

16.

Christophorou M, Ringshausen I, Finch A, Swigart L, Evan G . The pathological response to DNA damage does not contribute to p53-mediated tumour suppression. Nature. 2006; 443(7108):214-7. DOI: 10.1038/nature05077. View

17.

Chen S, Dai Y, Harada H, Dent P, Grant S . Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. Cancer Res. 2007; 67(2):782-91. DOI: 10.1158/0008-5472.CAN-06-3964. View

18.

Andarawewa K, Paupert J, Pal A, Barcellos-Hoff M . New rationales for using TGFbeta inhibitors in radiotherapy. Int J Radiat Biol. 2007; 83(11-12):803-11. DOI: 10.1080/09553000701711063. View

19.

Komarov P, Komarova E, Kondratov R, Coon J, Chernov M, Gudkov A . A chemical inhibitor of p53 that protects mice from the side effects of cancer therapy. Science. 1999; 285(5434):1733-7. DOI: 10.1126/science.285.5434.1733. View

20.

Nesslinger N, Sahota R, Stone B, Johnson K, Chima N, King C . Standard treatments induce antigen-specific immune responses in prostate cancer. Clin Cancer Res. 2007; 13(5):1493-502. DOI: 10.1158/1078-0432.CCR-06-1772. View